InvestSMART

PharmAust Limited (ASX: PAA) - Announcements

Current share price for PAA : $0.230 0.015 (6.98%)+

ASX company news and announcements for PharmAust Limited (PAA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PharmAust Limited (PAA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PharmAust Limited (PAA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PharmAust Limited (PAA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Phase II Dog Cancer Trial Commences 9 Sep 2019 9:08AM $0.125 $0.230 risen by 84%
- Investor Roadshow Presentation - September 2019 9 Sep 2019 8:26AM $0.125 $0.230 risen by 84%
- Preliminary Final Report 30 Aug 2019 7:23PM $0.105 $0.230 risen by 119.05%
- Appendix 3B & s708 notice 28 Aug 2019 7:28PM $0.100 $0.230 risen by 130%
- Receipt of GMP Grade Tablets for Phase II Trials 26 Aug 2019 9:31AM $0.094 $0.230 risen by 144.68%
- Change of Director's Interest Notice 16 Aug 2019 3:40PM $0.073 $0.230 risen by 215.07%
- Appendix 4C and Quarterly Update 31 Jul 2019 8:13AM $0.081 $0.230 risen by 183.95%
- Appendix 3B & s708 notice 26 Jul 2019 4:08PM $0.066 $0.230 risen by 248.48%
- Investor Presentation 25 Jul 2019 6:25PM $0.063 $0.230 risen by 265.08%
- Response to ASX Price and Volume Query 23 Jul 2019 2:23PM $0.068 $0.230 risen by 238.24%
- Pause In Trading 23 Jul 2019 1:56PM $0.065 $0.230 risen by 253.85%
- Change in substantial holding 23 Jul 2019 9:57AM $0.054 $0.230 risen by 325.93%
- PharmAust receives ethics approval to begin Phase II Trial 15 Jul 2019 8:29AM $0.050 $0.230 risen by 360%
- Epichem Final Loan Repayment Milestone for New Laboratory 2 Jul 2019 8:26AM $0.040 $0.230 risen by 475%
- PharmAust Commences GMP Tablet Manufacture for Phase 2 Trial 4 Jun 2019 8:31AM $0.039 $0.230 risen by 489.74%
- Receipt of 25kg of GMP-Grade Monepantel from Elanco 8 May 2019 10:26AM $0.036 $0.230 risen by 538.89%
- Phase I Canine Repeat Dose MPL Demonstrates High Performance 6 May 2019 9:13AM $0.033 $0.230 risen by 596.97%
- Appendix 4C and Quarterly Update 1 May 2019 8:27AM $0.035 $0.230 risen by 557.14%
- PharmAust Receives $672,250 R&D Tax Incentive Refund 30 Apr 2019 9:31AM $0.035 $0.230 risen by 557.14%
- Appendix 3B 24 Apr 2019 1:59PM $0.037 $0.230 risen by 521.62%
- Shortfall Placement Oversubscribed 11 Apr 2019 10:59AM $0.037 $0.230 risen by 521.62%
- Change of Director's Interest Notice x 4 29 Mar 2019 10:18AM $0.039 $0.230 risen by 489.74%
- Phase I Monepantel Tablets Demonstrate High Safety 28 Mar 2019 10:00AM $0.035 $0.230 risen by 557.14%
- PharmAust Raises $1.3m in Rights Issue 22 Mar 2019 9:34AM $0.035 $0.230 risen by 557.14%
- MPL Tablets Demonstrate Positive Performance in Phase 1 14 Mar 2019 8:24AM $0.032 $0.230 risen by 618.75%

401 - 425 of 796 results

Page 17 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.